Abstract
Both estrogen and androgen exert their antiosteoporotic effects, at least in part, by inhibiting IL-6 production, thereby suppressing osteoclastogenesis. Several observations, however, suggest that besides increased IL-6 production, sensitivity of the osteoclastogenic process to this cytokine is altered after ovariectomy. Based on this and evidence that the ligand-binding subunit of the IL-6 receptor (gp80) is a limiting factor for the actions of IL-6 on bone, we hypothesized that sex steroids regulate expression of the IL-6 receptor as well. We report that 17beta-estradiol or dihydrotestosterone in vitro decreased the abundance of the gp80 mRNA as well as the mRNA of the signal-transducing subunit of the IL-6 receptor (gp130) in cells of the bone marrow stromal/osteoblastic lineage, and also decreased gp130 protein levels. These effects did not require new protein synthesis. In contrast to sex steroids, parathyroid hormone stimulated gp130 expression; this effect was opposed by sex steroids. Consistent with these findings, ovariectomy in mice caused an increase in expression of gp80, gp130, and IL-6 mRNAs in ex vivo bone marrow cell cultures as determined by quantitative reverse transcription (RT)-PCR, and confirmed on an individual cell basis using in situ RT-PCR. The demonstration of increased expression of the IL-6 receptor after loss of sex steroids provides an explanation for why IL-6 is important for skeletal homeostasis in the sex steroid-deficient, but not replete, state.
Full Text
The Full Text of this article is available as a PDF (2.0 MB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bellido T., Borba V. Z., Roberson P., Manolagas S. C. Activation of the Janus kinase/STAT (signal transducer and activator of transcription) signal transduction pathway by interleukin-6-type cytokines promotes osteoblast differentiation. Endocrinology. 1997 Sep;138(9):3666–3676. doi: 10.1210/endo.138.9.5364. [DOI] [PubMed] [Google Scholar]
- Bellido T., Jilka R. L., Boyce B. F., Girasole G., Broxmeyer H., Dalrymple S. A., Murray R., Manolagas S. C. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J Clin Invest. 1995 Jun;95(6):2886–2895. doi: 10.1172/JCI117995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bellido T., Stahl N., Farruggella T. J., Borba V., Yancopoulos G. D., Manolagas S. C. Detection of receptors for interleukin-6, interleukin-11, leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in bone marrow stromal/osteoblastic cells. J Clin Invest. 1996 Jan 15;97(2):431–437. doi: 10.1172/JCI118432. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bismar H., Diel I., Ziegler R., Pfeilschifter J. Increased cytokine secretion by human bone marrow cells after menopause or discontinuation of estrogen replacement. J Clin Endocrinol Metab. 1995 Nov;80(11):3351–3355. doi: 10.1210/jcem.80.11.7593450. [DOI] [PubMed] [Google Scholar]
- Cosman F., Shen V., Xie F., Seibel M., Ratcliffe A., Lindsay R. Estrogen protection against bone resorbing effects of parathyroid hormone infusion. Assessment by use of biochemical markers. Ann Intern Med. 1993 Mar 1;118(5):337–343. doi: 10.7326/0003-4819-118-5-199303010-00003. [DOI] [PubMed] [Google Scholar]
- De Benedetti F., Massa M., Pignatti P., Albani S., Novick D., Martini A. Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest. 1994 May;93(5):2114–2119. doi: 10.1172/JCI117206. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Devlin R. D., Bone H. G., 3rd, Roodman G. D. Interleukin-6: a potential mediator of the massive osteolysis in patients with Gorham-Stout disease. J Clin Endocrinol Metab. 1996 May;81(5):1893–1897. doi: 10.1210/jcem.81.5.8626854. [DOI] [PubMed] [Google Scholar]
- Feyen J. H., Elford P., Di Padova F. E., Trechsel U. Interleukin-6 is produced by bone and modulated by parathyroid hormone. J Bone Miner Res. 1989 Aug;4(4):633–638. doi: 10.1002/jbmr.5650040422. [DOI] [PubMed] [Google Scholar]
- Fogh J., Wright W. C., Loveless J. D. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst. 1977 Feb;58(2):209–214. doi: 10.1093/jnci/58.2.209. [DOI] [PubMed] [Google Scholar]
- Girasole G., Jilka R. L., Passeri G., Boswell S., Boder G., Williams D. C., Manolagas S. C. 17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest. 1992 Mar;89(3):883–891. doi: 10.1172/JCI115668. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Girasole G., Passeri G., Jilka R. L., Manolagas S. C. Interleukin-11: a new cytokine critical for osteoclast development. J Clin Invest. 1994 Apr;93(4):1516–1524. doi: 10.1172/JCI117130. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Greenfield E. M., Shaw S. M., Gornik S. A., Banks M. A. Adenyl cyclase and interleukin 6 are downstream effectors of parathyroid hormone resulting in stimulation of bone resorption. J Clin Invest. 1995 Sep;96(3):1238–1244. doi: 10.1172/JCI118157. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Grey A., Mitnick M. A., Shapses S., Ellison A., Gundberg C., Insogna K. Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption--a clinical research center study. J Clin Endocrinol Metab. 1996 Oct;81(10):3450–3454. doi: 10.1210/jcem.81.10.8855783. [DOI] [PubMed] [Google Scholar]
- Heremans H., Billiau A., Cassiman J. J., Mulier J. C., de Somer P. In vitro cultivation of human tumor tissues. II. Morphological and virological characterization of three cell lines. Oncology. 1978;35(6):246–252. doi: 10.1159/000225298. [DOI] [PubMed] [Google Scholar]
- Ihle J. N. STATs: signal transducers and activators of transcription. Cell. 1996 Feb 9;84(3):331–334. doi: 10.1016/s0092-8674(00)81277-5. [DOI] [PubMed] [Google Scholar]
- Jilka R. L., Hangoc G., Girasole G., Passeri G., Williams D. C., Abrams J. S., Boyce B., Broxmeyer H., Manolagas S. C. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science. 1992 Jul 3;257(5066):88–91. doi: 10.1126/science.1621100. [DOI] [PubMed] [Google Scholar]
- Kassem M., Khosla S., Spelsberg T. C., Riggs B. L. Cytokine production in the bone marrow microenvironment: failure to demonstrate estrogen regulation in early postmenopausal women. J Clin Endocrinol Metab. 1996 Feb;81(2):513–518. doi: 10.1210/jcem.81.2.8636260. [DOI] [PubMed] [Google Scholar]
- Kishimoto T., Taga T., Akira S. Cytokine signal transduction. Cell. 1994 Jan 28;76(2):253–262. doi: 10.1016/0092-8674(94)90333-6. [DOI] [PubMed] [Google Scholar]
- Klein B., Wijdenes J., Zhang X. G., Jourdan M., Boiron J. M., Brochier J., Liautard J., Merlin M., Clement C., Morel-Fournier B. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood. 1991 Sep 1;78(5):1198–1204. [PubMed] [Google Scholar]
- Kotake S., Sato K., Kim K. J., Takahashi N., Udagawa N., Nakamura I., Yamaguchi A., Kishimoto T., Suda T., Kashiwazaki S. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res. 1996 Jan;11(1):88–95. doi: 10.1002/jbmr.5650110113. [DOI] [PubMed] [Google Scholar]
- Lakatos P., Foldes J., Horvath C., Kiss L., Tatrai A., Takacs I., Tarjan G., Stern P. H. Serum interleukin-6 and bone metabolism in patients with thyroid function disorders. J Clin Endocrinol Metab. 1997 Jan;82(1):78–81. doi: 10.1210/jcem.82.1.3641. [DOI] [PubMed] [Google Scholar]
- Langub M. C., Jr, Koszewski N. J., Turner H. V., Monier-Faugere M. C., Geng Z., Malluche H. H. Bone resorption and mRNA expression of IL-6 and IL-6 receptor in patients with renal osteodystrophy. Kidney Int. 1996 Aug;50(2):515–520. doi: 10.1038/ki.1996.343. [DOI] [PubMed] [Google Scholar]
- Lis J., Wu C. Protein traffic on the heat shock promoter: parking, stalling, and trucking along. Cell. 1993 Jul 16;74(1):1–4. doi: 10.1016/0092-8674(93)90286-y. [DOI] [PubMed] [Google Scholar]
- Löwik C. W., van der Pluijm G., Bloys H., Hoekman K., Bijvoet O. L., Aarden L. A., Papapoulos S. E. Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis. Biochem Biophys Res Commun. 1989 Aug 15;162(3):1546–1552. doi: 10.1016/0006-291x(89)90851-6. [DOI] [PubMed] [Google Scholar]
- Malik N., Haugen H. S., Modrell B., Shoyab M., Clegg C. H. Developmental abnormalities in mice transgenic for bovine oncostatin M. Mol Cell Biol. 1995 May;15(5):2349–2358. doi: 10.1128/mcb.15.5.2349. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Manolagas S. C., Jilka R. L. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med. 1995 Feb 2;332(5):305–311. doi: 10.1056/NEJM199502023320506. [DOI] [PubMed] [Google Scholar]
- McKane W. R., Khosla S., Peterson J. M., Egan K., Riggs B. L. Circulating levels of cytokines that modulate bone resorption: effects of age and menopause in women. J Bone Miner Res. 1994 Aug;9(8):1313–1318. doi: 10.1002/jbmr.5650090821. [DOI] [PubMed] [Google Scholar]
- Metcalf D., Gearing D. P. Fatal syndrome in mice engrafted with cells producing high levels of the leukemia inhibitory factor. Proc Natl Acad Sci U S A. 1989 Aug;86(15):5948–5952. doi: 10.1073/pnas.86.15.5948. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Miyaura C., Kusano K., Masuzawa T., Chaki O., Onoe Y., Aoyagi M., Sasaki T., Tamura T., Koishihara Y., Ohsugi Y. Endogenous bone-resorbing factors in estrogen deficiency: cooperative effects of IL-1 and IL-6. J Bone Miner Res. 1995 Sep;10(9):1365–1373. doi: 10.1002/jbmr.5650100914. [DOI] [PubMed] [Google Scholar]
- Mocharla H., Butch A. W., Pappas A. A., Flick J. T., Weinstein R. S., De Togni P., Jilka R. L., Roberson P. K., Parfitt A. M., Manolagas S. C. Quantification of vitamin D receptor mRNA by competitive polymerase chain reaction in PBMC: lack of correspondence with common allelic variants. J Bone Miner Res. 1997 May;12(5):726–733. doi: 10.1359/jbmr.1997.12.5.726. [DOI] [PubMed] [Google Scholar]
- Murakami-Mori K., Taga T., Kishimoto T., Nakamura S. AIDS-associated Kaposi's sarcoma (KS) cells express oncostatin M (OM)-specific receptor but not leukemia inhibitory factor/OM receptor or interleukin-6 receptor. Complete block of OM-induced KS cell growth and OM binding by anti-gp130 antibodies. J Clin Invest. 1995 Sep;96(3):1319–1327. doi: 10.1172/JCI118167. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Owen T. A., Aronow M. S., Barone L. M., Bettencourt B., Stein G. S., Lian J. B. Pleiotropic effects of vitamin D on osteoblast gene expression are related to the proliferative and differentiated state of the bone cell phenotype: dependency upon basal levels of gene expression, duration of exposure, and bone matrix competency in normal rat osteoblast cultures. Endocrinology. 1991 Mar;128(3):1496–1504. doi: 10.1210/endo-128-3-1496. [DOI] [PubMed] [Google Scholar]
- Passeri G., Girasole G., Jilka R. L., Manolagas S. C. Increased interleukin-6 production by murine bone marrow and bone cells after estrogen withdrawal. Endocrinology. 1993 Aug;133(2):822–828. doi: 10.1210/endo.133.2.8393776. [DOI] [PubMed] [Google Scholar]
- Poli V., Balena R., Fattori E., Markatos A., Yamamoto M., Tanaka H., Ciliberto G., Rodan G. A., Costantini F. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 1994 Mar 1;13(5):1189–1196. doi: 10.1002/j.1460-2075.1994.tb06368.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pottratz S. T., Bellido T., Mocharla H., Crabb D., Manolagas S. C. 17 beta-Estradiol inhibits expression of human interleukin-6 promoter-reporter constructs by a receptor-dependent mechanism. J Clin Invest. 1994 Mar;93(3):944–950. doi: 10.1172/JCI117100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ray A., Prefontaine K. E., Ray P. Down-modulation of interleukin-6 gene expression by 17 beta-estradiol in the absence of high affinity DNA binding by the estrogen receptor. J Biol Chem. 1994 Apr 29;269(17):12940–12946. [PubMed] [Google Scholar]
- Romas E., Udagawa N., Zhou H., Tamura T., Saito M., Taga T., Hilton D. J., Suda T., Ng K. W., Martin T. J. The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures. J Exp Med. 1996 Jun 1;183(6):2581–2591. doi: 10.1084/jem.183.6.2581. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Roodman G. D., Kurihara N., Ohsaki Y., Kukita A., Hosking D., Demulder A., Smith J. F., Singer F. R. Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone. J Clin Invest. 1992 Jan;89(1):46–52. doi: 10.1172/JCI115584. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Saito M., Yoshida K., Hibi M., Taga T., Kishimoto T. Molecular cloning of a murine IL-6 receptor-associated signal transducer, gp130, and its regulated expression in vivo. J Immunol. 1992 Jun 15;148(12):4066–4071. [PubMed] [Google Scholar]
- Sakagami Y., Girasole G., Yu X. P., Boswell H. S., Manolagas S. C. Stimulation of interleukin-6 production by either calcitonin gene-related peptide or parathyroid hormone in two phenotypically distinct bone marrow-derived murine stromal cell lines. J Bone Miner Res. 1993 Jul;8(7):811–816. doi: 10.1002/jbmr.5650080706. [DOI] [PubMed] [Google Scholar]
- Salvi M., Girasole G., Pedrazzoni M., Passeri M., Giuliani N., Minelli R., Braverman L. E., Roti E. Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease. J Clin Endocrinol Metab. 1996 Aug;81(8):2976–2979. doi: 10.1210/jcem.81.8.8768861. [DOI] [PubMed] [Google Scholar]
- Schoester M., Heinrich P. C., Graeve L. Regulation of interleukin-6 receptor expression by interleukin-6 in human monocytes--a re-examination. FEBS Lett. 1994 May 30;345(2-3):131–134. doi: 10.1016/0014-5793(94)00416-1. [DOI] [PubMed] [Google Scholar]
- Schooltink H., Schmitz-Van de Leur H., Heinrich P. C., Rose-John S. Up-regulation of the interleukin-6-signal transducing protein (gp130) by interleukin-6 and dexamethasone in HepG2 cells. FEBS Lett. 1992 Feb 10;297(3):263–265. doi: 10.1016/0014-5793(92)80552-r. [DOI] [PubMed] [Google Scholar]
- Sidell N., Taga T., Hirano T., Kishimoto T., Saxon A. Retinoic acid-induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors. J Immunol. 1991 Jun 1;146(11):3809–3814. [PubMed] [Google Scholar]
- Snyers L., Content J. Enhancement of IL-6 receptor beta chain (gp130) expression by IL-6, IL-1 and TNF in human epithelial cells. Biochem Biophys Res Commun. 1992 Jun 30;185(3):902–908. doi: 10.1016/0006-291x(92)91712-y. [DOI] [PubMed] [Google Scholar]
- Stahl N., Davis S., Wong V., Taga T., Kishimoto T., Ip N. Y., Yancopoulos G. D. Cross-linking identifies leukemia inhibitory factor-binding protein as a ciliary neurotrophic factor receptor component. J Biol Chem. 1993 Apr 15;268(11):7628–7631. [PubMed] [Google Scholar]
- Stein B., Yang M. X. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta. Mol Cell Biol. 1995 Sep;15(9):4971–4979. doi: 10.1128/mcb.15.9.4971. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sudo H., Kodama H. A., Amagai Y., Yamamoto S., Kasai S. In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. J Cell Biol. 1983 Jan;96(1):191–198. doi: 10.1083/jcb.96.1.191. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tamura T., Udagawa N., Takahashi N., Miyaura C., Tanaka S., Yamada Y., Koishihara Y., Ohsugi Y., Kumaki K., Taga T. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11924–11928. doi: 10.1073/pnas.90.24.11924. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ware C. B., Horowitz M. C., Renshaw B. R., Hunt J. S., Liggitt D., Koblar S. A., Gliniak B. C., McKenna H. J., Papayannopoulou T., Thoma B. Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death. Development. 1995 May;121(5):1283–1299. doi: 10.1242/dev.121.5.1283. [DOI] [PubMed] [Google Scholar]
- Yamamoto T., Ozono K., Kasayama S., Yoh K., Hiroshima K., Takagi M., Matsumoto S., Michigami T., Yamaoka K., Kishimoto T. Increased IL-6-production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright syndrome. J Clin Invest. 1996 Jul 1;98(1):30–35. doi: 10.1172/JCI118773. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zhong Z., Wen Z., Darnell J. E., Jr Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science. 1994 Apr 1;264(5155):95–98. doi: 10.1126/science.8140422. [DOI] [PubMed] [Google Scholar]
- Zuckerman S. H., Bryan-Poole N., Evans G. F., Short L., Glasebrook A. L. In vivo modulation of murine serum tumour necrosis factor and interleukin-6 levels during endotoxemia by oestrogen agonists and antagonists. Immunology. 1995 Sep;86(1):18–24. [PMC free article] [PubMed] [Google Scholar]
- de la Mata J., Uy H. L., Guise T. A., Story B., Boyce B. F., Mundy G. R., Roodman G. D. Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J Clin Invest. 1995 Jun;95(6):2846–2852. doi: 10.1172/JCI117990. [DOI] [PMC free article] [PubMed] [Google Scholar]